Patents by Inventor Gregory J. Archambeau
Gregory J. Archambeau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20100098687Abstract: Provided are methods for treating a TSLP-mediated or TSLPR-mediated disease or condition, comprising administration of an electrokinetically altered aqueous fluid comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures substantially having an average diameter of less than about 100 nanometers and stably configured in the ionic aqueous fluid in an amount sufficient for treating a TSLP-mediated or TSLPR-mediated disease or condition. The charge-stabilized oxygen-containing nanostructures are preferably stably configured in the fluid in an amount sufficient to provide for modulation of cellular membrane potential and/or conductivity. Certain aspects comprising modulation or down-regulation of TSLP expression and/or activity have utility for treating TSLP-mediated or TSLPR-mediated diseases or conditions as disclosed herein (e.g.Type: ApplicationFiled: October 22, 2009Publication date: April 22, 2010Applicant: Revalesio CorporationInventors: Richard L. Watson, Anthony B. Wood, Gregory J. Archambeau
-
Publication number: 20100098659Abstract: Provided are methods for treating an MMP9-mediated condition or disease, comprising administration of an electrokinetically altered aqueous fluid comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures substantially having an average diameter of less than about 100 nanometers and stably configured in the ionic aqueous fluid in an amount sufficient for treating an MMP9-mediated condition or disease. The charge-stabilized oxygen-containing nanostructures are preferably stably configured in the fluid in an amount sufficient to provide for modulation of cellular membrane potential and/or conductivity. Certain aspects comprising modulation or down-regulation of MMP-9 expression and/or activity have utility for treating MMP9-mediated diseases or conditions as disclosed herein (e.g.Type: ApplicationFiled: October 22, 2009Publication date: April 22, 2010Applicant: Revalesio CorporationInventors: Richard L. Watson, Anthony B. Wood, Gregory J. Archambeau
-
Publication number: 20100038244Abstract: Provided are electrokinetically-altered fluids (e.g., gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity. Further provided are the methods of making the electrokinetically-altered ionic aqueous fluid compositions. Particular aspects provide for regulating or modulating intracellular signal transduction associated by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular methods of producing the electrokinetically-altered fluids.Type: ApplicationFiled: April 30, 2009Publication date: February 18, 2010Applicant: Revalesio CorporationInventors: Anthony B. Wood, Gregory J. Archambeau, Richard L. Watson
-
COMPOSITIONS AND METHODS FOR MODULATING CELLULAR MEMBRANE-MEDIATED INTRACELLULAR SIGNAL TRANSDUCTION
Publication number: 20100029764Abstract: Provided are electrokinetically-altered fluids (e.g., gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity. Particular aspects of the present invention provide compositions and methods suitable for modulation of at least one of cellular membrane potential and cellular membrane conductivity. Additional aspects provide compositions and methods suitable for modulating intracellular signal transduction, including modulation of at least one of membrane structure, membrane potential or membrane conductivity, membrane proteins or receptors, ion channels, and calcium dependant cellular messaging systems, comprising use of the inventive electrokinetically altered solutions to impart electrochemical and/or conformational changes in membranous structures (e.g.Type: ApplicationFiled: May 4, 2009Publication date: February 4, 2010Applicant: Revalesio CorporationInventors: Richard L. Watson, Anthony B. Wood, Gregory J. Archambeau -
Publication number: 20100028441Abstract: Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating inflammatory neurodegenerative condition or disease or at least one symptom thereof. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ioinic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g.Type: ApplicationFiled: April 27, 2009Publication date: February 4, 2010Applicant: Revalesio CorporationInventors: Richard L. Watson, Anthony B. Wood, Gregory J. Archambeau
-
Publication number: 20100028443Abstract: Provided are electrokinetically-altered fluids (gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for using same in treating inflammation or at least one symptom thereof. The electrokinetically-altered fluid compositions and methods include electrokinetically-altered ionic aqueous fluids optionally in combination with other therapeutic agents.Type: ApplicationFiled: April 30, 2009Publication date: February 4, 2010Applicant: Revalesio CorporationInventors: Richard L. Watson, Anthony B. Wood, Gregory J. Archambeau
-
Publication number: 20100028442Abstract: Provided are electrokinetically-altered aqueous fluids (e.g., gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating an irritation, infection or inflammatory eye condition, comprising administering to, by contacting the eye of a subject in need thereof a therapeutically effective amount of an electrokinetically-altered aqueous fluid. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ioinic aqueous fluids optionally in combination with other therapeutic agents. Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g.Type: ApplicationFiled: April 28, 2009Publication date: February 4, 2010Applicant: Revalesio CorporationInventors: Gregory J. Archambeau, Anthony B. Wood, Richard L. Watson
-
Patent number: 7654728Abstract: A system and method for generating an oxygen enriched aqueous solution for therapeutic application includes a diffuser comprising a first diffusing member having a surface incorporating surface disturbances, and a second diffusing member positioned relative to the first diffusing member to form a channel through which an aqueous solution and oxygen gas may flow. A reservoir containing the aqueous solution is connected to a pump that draws the aqueous solution from the reservoir and inputs the aqueous solution into the diffuser. The aqueous solution is moved through the channel relative to the surface disturbances to create cavitation in the aqueous solution to diffuse the oxygen gas into the aqueous solution to produce an oxygen enriched aqueous solution.Type: GrantFiled: June 25, 2004Date of Patent: February 2, 2010Assignee: Revalesio CorporationInventors: Anthony B. Wood, Gregory J. Archambeau, Richard A. Klena
-
Publication number: 20100021464Abstract: Provided are electrokinetically-altered fluids (e.g., gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating a wound to a surface tissue or a symptom thereof. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ionic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g.Type: ApplicationFiled: April 28, 2009Publication date: January 28, 2010Applicant: Revalesio CorporationInventors: Gregory J. Archambeau, Richard L. Watson, Anthony B. Wood
-
Publication number: 20100015235Abstract: Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating inflammatory neurodegenerative condition or disease or at least one symptom thereof. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ionic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g.Type: ApplicationFiled: May 1, 2009Publication date: January 21, 2010Applicant: Revalesio CorporationInventors: Richard L. Watson, Anthony B. Wood, Gregory J. Archambeau
-
Publication number: 20100009008Abstract: Particular aspects provide compositions and methods for treating bacterial infection or at least one symptom related to bacterial infection in a subject in need thereof by administering a therapeutic composition comprising at least one electrokinetically-altered fluid (including gas-enriched electrokinetically altered fluids) which comprise an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity. The electrokinetically-altered ionic fluid compositions are sufficient to provide for modulation of intracellular signal transduction, wherein treating bacterial infection or at least one symptom related to bacterial infection is thereby afforded.Type: ApplicationFiled: May 4, 2009Publication date: January 14, 2010Applicant: Revalesio CorporationInventors: Richard L. Watson, Anthony B. Wood, Gregory J. Archambeau
-
Publication number: 20100008997Abstract: Provided are compositions and methods for treating lung or respiratory disorders or conditions characterized by airflow obstruction or limitation, or a symptom thereof (e.g., asthma, rhinitis, allergic rhinitis, and chronic obstructive pulmonary disease (COPD) and COPD-associated conditions (e.g., bronchitis, emphysema, asthma), emphysema, pneumonia, bronchitis, influenza, SARS, tuberculosis, and whooping cough (pertussis), and the like) in a subject in need thereof by administering a therapeutic composition comprising at least one electrokinetically altered fluid (gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures as disclosed herein. In certain aspects, the methods comprise regulating intracellular signal transduction by modulation of at least one of cellular membranes, membrane potential, membrane proteins (e.g., membrane receptors, (e.g., to G protein coupled receptors, and intercellular junctions)).Type: ApplicationFiled: May 1, 2009Publication date: January 14, 2010Applicant: Revalesio CorporationInventors: Richard L. Watson, Anthony B. Wood, Gregory J. Archambeau
-
Publication number: 20100004189Abstract: Provided are electrokinetically-altered fluids (gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for using same in treating cystic fibrosis or a symptom thereof. The electrokinetically-altered fluid compositions and methods include electrokinetically-altered fluids optionally in combination with other therapeutic agents (e.g., antibiotics, albuterol, budesonide, etc.). Particular embodiments comprise use and/or synergy with tobramycin for treating bacterial infection, and use and/or synergy with a bronchiodilator.Type: ApplicationFiled: May 1, 2009Publication date: January 7, 2010Applicant: Revalesio CorporationInventors: Richard L. Watson, Anthony B. Wood, Gregory J. Archambeau
-
Publication number: 20100003333Abstract: Provided are electrokinetically-altered fluids (e.g., gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for using same in treating digestive disorders or at least one symptom thereof. The electrokinetically-altered fluid compositions and methods include electrokinetically-altered ioinic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said digestive disorders by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g.Type: ApplicationFiled: April 29, 2009Publication date: January 7, 2010Applicant: Revalesio CorporationInventors: Richard L. Watson, Anthony B. Wood, Gregory J. Archambeau
-
Publication number: 20090274771Abstract: Provided are compositions and methods for treating or preventing lung or respiratory disorders or conditions characterized by airflow obstruction or limitation, or a symptom thereof (e.g., asthma, rhinitis, allergic rhinitis (e.g. nose respiratory tract), and chronic obstructive pulmonary disease (COPD) and COPD-associated conditions (e.g., bronchitis, emphysema, asthma), emphysema, pneumonia, bronchitis, influenza, SARS, tuberculosis, and whooping cough (pertussis), and the like) in a subject in need thereof by administering a therapeutic composition comprising at least one electrokinetically generated fluid (including gas-enriched electrokinetically generated fluids) as disclosed herein, the electrokinetically altered aqueous fluid suitable to alter cellular membrane structure or function sufficient to provide for modulation of intracellular signal transduction, wherein treating a lung disorder or a symptom thereof is thereby afforded.Type: ApplicationFiled: October 27, 2008Publication date: November 5, 2009Applicant: Revalesio CorporationInventors: Richard L. Watson, Anthony B. Wood, Gregory J. Archambeau
-
Publication number: 20090274730Abstract: Provided are electrokinetically-generated fluids (e.g., gas-enriched electrokinetic fluids or solutions), and therapeutic compositions and methods for use in treating inflammation or at least one symptom of inflammation. The electrokinetically-generated fluids or therapeutic compositions and methods include electrokinetically-generated aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-generated fluids (e.g.Type: ApplicationFiled: October 24, 2008Publication date: November 5, 2009Applicant: Revalesio CorporationInventors: Richard L. Watson, Anthony B. Wood, Gregory J. Archambeau
-
Publication number: 20090263495Abstract: Particular aspects provide compositions and methods for treating or preventing bacterial infection or at least one symptom related to bacterial infection, and the like in a subject in need thereof by administering a therapeutic composition comprising at least one electrokinetically generated fluid (including gas-enriched electrokinetically generated fluids) as disclosed herein, the electrokinetically altered aqueous fluid suitable to alter cellular membrane structure or function sufficient to provide for modulation of intracellular signal transduction, wherein treating bacterial infection or at least one symptom related to bacterial infection is thereby afforded. In particular embodiments, the fluids are gas-enriched fluids or therapeutic compositions and methods, and include oxygen-enriched water optionally in combination with other therapeutic agents. Other embodiments include particular routes of administration or formulations for the gas-enriched therapeutic compositions.Type: ApplicationFiled: October 23, 2008Publication date: October 22, 2009Applicant: REVALESIO CORPORATIONInventors: Richard L. Watson, Anthony B. Wood, Gregory J. Archambeau
-
Publication number: 20090247458Abstract: Particular aspects provide electrokinetically-generated fluids (e.g., electrokinetically-generated gas-enriched fluids and solutions), and therapeutic compositions and methods comprising use thereof in treating at least one symptom of cystic fibrosis. In particular embodiments, at least one symptom of cystic fibrosis treated by the present invention include inhibition of Pseudomonas infection, synergy with tobramycin (including TOBI) for use against bacterial infection, and synergy with a bronchiodilator. In particular embodiments, the electrokinetically-generated fluids or therapeutic compositions and methods comprise combination with other therapeutic agents (e.g., antibiotics, albuterol, budesonide, etc.).Type: ApplicationFiled: October 24, 2008Publication date: October 1, 2009Applicant: Revalesio CorporationInventors: Richard L. Watson, Anthony B. Wood, Gregory J. Archambeau
-
COMPOSITIONS AND METHODS FOR MODULATING CELLULAR MEMBRANE-MEDIATED INTRACELLULAR SIGNAL TRANSDUCTION
Publication number: 20090227018Abstract: Particular aspects of the present invention provide compositions and methods for modulating intracellular signal transduction, including modulation of at least one of membrane structure, membrane potential or membrane conductivity, membrane proteins or receptors, ion channels, and calcium dependant cellular messaging systems, comprising use of the inventive electrokinetically generated solutions to impart electrochemical and/or conformational changes in membranous structures (e.g., membrane and/or membrane proteins, receptors or other components) including but not limited to G-protein coupled receptors (GPCRs) and/or G-proteins, and intracellular junctions. In particular embodiments, the electrokinetically generated solutions or compositions are gas-enriched and/or comprise other therapeutic agents. Other embodiments include particular therapeutic methods comprising administration or formulations of the therapeutic compositions, and in various combination treatments.Type: ApplicationFiled: October 23, 2008Publication date: September 10, 2009Applicant: Revalesio CorporationInventors: Richard L. Watson, Anthony B. Wood, Gregory J. Archambeau -
Publication number: 20080281001Abstract: Particular aspects provide compositions comprising an electrokinetically altered oxygenated aqueous fluid, wherein the oxygen in the fluid is present in an amount of at least 25 ppm. In certain aspects, the electrokinetically altered oxygenated aqueous fluid comprises electrokinetically modified or charged oxygen species present in an amount of at least 0.5 ppm. In certain aspects the electrokinetically altered oxygenated aqueous fluid comprises solvated electrons stabilized by molecular oxygen, and wherein the solvated electrons present in an amount of at least 0.01 ppm. In certain aspects, the fluid facilitates oxidation of pyrogallol to purpurogallin in the presence of horseradish peroxidase enzyme (HRP) in an amount above that afforded by a control pressure pot generated or fine-bubble generated aqueous fluid having an equivalent dissolved oxygen level, and wherein there is no hydrogen peroxide, or less than 0.1 ppm of hydrogen peroxide present in the electrokinetic oxygen-enriched aqueous fluid.Type: ApplicationFiled: October 25, 2007Publication date: November 13, 2008Applicant: Revalesio CorporationInventors: Anthony B. Wood, Gregory J. Archambeau, Richard L. Watson